Twelve Weeks Sofosbuvir/Daclatasvir in HCV Infected Children Aged 6-18 Years

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
Recently the era of direct-acting antiviral drugs for hepatitis C treatment has changed the world map of HCV. Results in adults are promising. FDA approved only two drugs in the pediatric age group 12 to 17 years. Younger children are still on the wait list for treatment. The current study aimed to study the efficacy and safety of combined sofosbuvir (SOF)/daclatasvir (DCV) in children with hepatitis C virus infection aged 6-18 years.
Epistemonikos ID: 1b612085e330d7fc69247e0e8f28a53c53d01388
First added on: Oct 31, 2026